A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Antigen Dose-Escalation and Adjuvant Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Varicella zoster virus vaccine (Primary)
- Indications Herpes zoster
- Focus Adverse reactions
- Sponsors Curevo Vaccine
- 26 Sep 2019 According to a Curevo Vaccine media release, interim results were presented in an oral presentation at the 44th annual International Herpesvirus Workshop in Knoxville, Tennessee.
- 26 Sep 2019 Interim results presented in a Curevo Vaccine media release.
- 08 Aug 2019 Status changed from recruiting to active, no longer recruiting.